The presence of the endogenous Leishmania RNA virus 1 (LRV1) replicating stably within some parasite species has been associated with the development of more severe forms of leishmaniasis and relapses after drug treatment in humans. Here, we show that the disease exacerbatory role of LRV1 relies on Type I interferon (Type I IFNs) production by macrophages and signaling in vivo. Moreover, infecting mice with the LRV1-cured L. guyanensis (LgyLRV1 -) strain of parasites followed by Type I IFN treatment increased lesion size and parasite burden, quantitatively reproducing the LRV1-bearing (LgyLRV1+) 
co-infection after the healing of leishmaniasis induced disease reactivation, overriding the protective adaptive immune response. Thus, viral infections may be a significant risk factor contributing to the pathological spectrum of human leishmaniasis.
Introduction
Leishmania are protozoan parasites, transmitted as unicellular promastigote forms by sand flies to their mammalian host (humans and dogs). In the skin, Leishmania parasites are phagocytized by tissue resident macrophages, where they survive intracellularly and proliferate as amastigotes. Infection with Leishmania parasites may lead to the development of leishmaniasis, affecting over 12 million people worldwide (1, 2) . Leishmaniasis may have different outcomes, ranging from localized cutaneous leishmaniasis to visceral leishmaniasis (1, 2) . Infection with L. guyanensis (Lgy) or L. braziliensis (Lbr) principally leads to simple cutaneous lesions, however, up to 10% of patients develop disseminated or mucocutaneous leishmaniasis. These latter more severe forms of the disease are characterized by the dissemination of the parasites from the primary infection site. Another complication of Lgy or Lbr infection can be relapse, which may occur months to years after the healing of the primary lesion, or after a first line drug treatment (3, 4) . Recently, we correlated the development of these more severe forms of leishmaniasis with the presence of Leishmania RNA virus (LRV1) within different species of Leishmania (3) (4) (5) (6) . Discovered in the 1980s (7, 8) , and since then for a long time neglected, Leishmaniavirus is a genus of double stranded RNA viruses belonging to the Totiviridae family. Like most other viruses in this family, LRV1 is neither shed nor infectious, and thus can be seen as a persistent, endogenous viral element (9) . Two species of LRV have been identified. The LRV1 species is principally found in South America within Lgy and Lbr (10, 11) , and the LRV2 species is found within L. major and L. aethiopica in the Old World (6, 12) 
. The increasing reports of LRVs in different
Leishmania species could imply a wider role in determining the fate of infection in humans.
However, in some instances, metastasis and relapse after drug treatment also occur in the absence of LRV1 (13). The basis for these discrepancies is of considerable interest, the hypothesis put forward include the significance of the presence of other parasite species, microbial or host factors that are known to play an important role in the development of MCL (14-16).
The disease-exacerbatory role of LRV1 relies principally on its modulation of the innate immune system via its dsRNA genome (5) . We recently showed that LRV1-dependent IL-17 promotes the dissemination of the parasite and the consequent formation of metastatic lesions (17) . Moreover, we demonstrated that LRV1 increases the life span of Lgy-infected macrophages through a Toll-like receptor 3 (TLR3) and Akt dependent pathway (18). Further, LRV-containing parasites promote TLR3-dependent secretion of pro-inflammatory cytokines and chemokines, including interferon-β (IFN-β) (5) . Interestingly, ablation of LRV1 using the parasite RNAi machinery, or by treatment with compounds selectively inhibiting LRV1, completely abrogated the production of pro-inflammatory cytokines by infected macrophages (19, 20) .
The induction of TLR3-dependent interferon-β production following infection with LRV1+ parasites suggested a potential role in the pathway leading to elevated pathogenicity. In this study, we investigated the disease exacerbatory role of viral-induced Type I IFNs in Lgy infection, not only with LRV1-bearing Lgy (LgyLRV1+), but also by co-infecting mice with LRV1-cured Lgy (LgyLRV1 -) and Lymphocytic Choriomeningitis virus (LCMV), or Toscana virus (TOSV).
Results

Type I IFNs exacerbate LgyLRV1+ infection
We first analyzed whether Type I IFNs could modulate the pathogenicity of Lgy. C57BL/6 wild type (WT) or Type I IFN receptor deficient (ifnar-/-) mice were infected with LgyLRV1 -or LgyLRV1+ parasites. Two weeks post infection, WT mice began to develop lesions that grew until reaching a maximal size at week 5 which then healed 4 weeks later, with LgyLRV1+ infection inducing significantly larger lesions compared to LgyLRV1 -infected mice (Fig. 1A) . In contrast, LgyLRV1+ infected ifnar-/-mice developed significantly smaller lesions, similar to those developed by ifnar-/-and WT mice infected with LgyLRV1 - (Fig. 1A) . Parasite numbers were also significantly increased in WT mice infected with LgyLRV1+ compared to the LgyLRV1 -infected counterpart (Fig. 1B) . Again, no difference was observed between ifnar-/-mice, independent of the presence of LRV1 in the infecting parasite, as the parasite load was similar to LgyLRV1 -infected WT mice. Thus, the deleterious effect of Type I IFNs includes worsening of lesion pathology and increased parasite numbers.
To further confirm the deleterious role of Type I IFNs, WT mice were injected with recombinant IFN-β (IFN-β) at early time points post Lgy infection, to mimic the anti-viral response induced by the endogenous dsRNA LRV1 virus (5) . In LgyLRV1 -infected mice, IFN-β showed a dose-dependent effect in increasing the lesion size and the parasite load at the peak of infection. In fact, injection of 100U of IFN-β showed a moderate increase in lesion size and no effect on parasite load, whereas injection of 500U or 1000U caused greater increase of both lesion size and parasite burden, quantitatively reproducing the phenotype of LgyLRV1+ infection (Fig. 1C-D) . In contrast, little effect from IFN-β treatment was seen in LgyLRV1+ infected mice, (Fig. 1E-F) . Similar results were obtained with IFN-α treatment (Fig. S1 ).
Viral co-infection increases the severity of Lgy leishmaniasis
The data above, in combination with previous findings (5), suggest that the endogenous dsRNA virus LRV1 acts to promote Lgy virulence through TLR3 and Type I interferon signaling. This alluded to the possibility that other agents triggering Type I interferon responses might act similarly to promote Leishmania virulence, such as coinfections with other viruses. To test this, we co-infected mice with LgyLRV1 -parasites and lymphocytic choriomeningitis virus Armstrong (LCMV), an arenavirus which induces a potent Type I IFN response (37). Two different sites of injection were used, intra-peritoneal injection for LCMV and subcutaneous in the footpad for Lgy.
Infection with LCMV Armstrong was shown to be cleared in 8 days by C57BL/6 WT mice with a robust T cell response (38). Viral titration in mouse serum, following intraperitoneal inoculation, showed only transient and very low viremia (39). As previously reported (40), the presence of Leishmania parasites did not increase LCMV infection (Fig.   S2) . Similarly, the concentration of Type I IFNs in the serum after 24 hours of LCMV infection was comparable between mice infected or not with Lgy (Fig. S3 ). These data demonstrated that the development of the LCMV infection was not affected by the presence of Lgy parasites. Interestingly, Type I IFNs were not detected in mouse blood following single infection with LgyLRV1+, suggesting that in this particular case the Type I IFN response is only local (Fig. S3 ).
We subsequently investigated whether LCMV-induced Type I IFNs stimulated gene expression at the site of Leishmania infection. We observed that genes known to be stimulated by Type I IFNs (oas1a, oas2, oasl2 or pkr) were significantly up-regulated in mice infected with LgyLRV1+, or with LgyLRV1 -co-infected with LCMV, compared to LgyLRV1 -infected mice (Fig. S3 ).
We then tested the effect of LCMV co-infection on the progression of leishmaniasis.
LCMV injection in LgyLRV1 -infected mice significantly worsened the outcome of leishmaniasis, increasing both pathology and parasite burden, which were very similar to the phenotype induced by LgyLRV1+ infection ( Fig. 2A and C) . The LCMV aggravation of Lgyinduced leishmaniasis completely relied on Type I IFNs, as no difference was observed when LCMV was injected into LgyLRV1 -infected ifnar-/-mice, neither with regard to footpad swelling nor parasite burden. ifnar-/-mice failed to rapidly clear the virus due to the absence of a proper Type I IFN response (Fig. S2) (41) . Moreover, this effect could again be related to the Type I IFN level, since, as already shown in the Type I IFNs injection experiment, no significant effect was observed when LCMV was injected in LgyLRV1+ infected mice ( Fig. 2 B and D).
We furthermore asked if another virus could similarly affect the course of leishmaniasis. We focused on Toscana virus (TOSV), a phlebovirus transmitted to humans by the same insect vector as Leishmania parasites (42). Mimicking the likely biological route of concomitant infection, TOSV was inoculated together with Lgy parasites subcutaneously into the footpad. As observed with LCMV, LgyLRV1 -/TOSV co-infection highly increased footpad swelling and parasite burden at the peak of infection (Fig. 2E-F) . ifnar-/-mice were susceptible to TOSV infection, with over 50% of mortality after two weeks of infection, precluding further tests on the Type I IFN dependency in this co-infection model.
Viral co-infection modulates macrophage responsiveness to IFN-γ through Type I IFNs
The data above suggested that co-infection with exogenous RNA viruses resulted in worsening of leishmaniasis, quantitatively similar to that seen by parasites bearing endogenous LRV1. We thus focused on defining potential mechanisms responsible for these exacerbated phenotypes. The immune system efficiently clears intracellular Leishmania (Fig. 3B) , however, the downregulation of IFN-γR expression was observed when mice were infected with LgyLRV1 -and injected with IFN-α or IFN-β (Fig. 3C ). This confirmed that the effect depended on Type I IFNs.
LCMV -Lgy co-infection accelerates parasite dissemination
The importance of IFN-γ was further demonstrated as a critical component of our murine model for metastatic leishmaniasis, where IFN-γ-/-mice failed to control Lgy infection, causing multiple metastatic lesions, usually located on the tail (17). In this model, metastases were accelerated in the presence of the endogenous LRV1 within Lgy parasites.
Interestingly, IFN-γ-/-mice co-infected with LgyLRV1 -/LCMV developed metastasis earlier than those infected with LgyLRV1 -alone, thus reproducing the phenotype of LgyLRV1+ parasites. Therefore, exogenous viral co-infection was equally capable of synergizing parasite virulence and metastasis (Fig. 4A-C) .
LCMV infection induces reactivation of leishmaniasis
We then asked whether viral infection could lead to reactivation of leishmaniasis following healing, a pathological situation often observed in humans (45). LCMV injection subsequent to lesion healing induced reactivation of the disease, with a reappearance of both lesion pathology and increased parasite numbers, overriding the protective adaptive immune response essential in C57BL/6 mice re-infected with Lgy (Fig. S6 ). Once reactivated, pathology and parasite burden progressed very similarly to that seen in concomitant LgyLRV1 -/LCMV infections, with the lesion pathology and size peaking around 5 weeks post LCMV injection and healing a few weeks later (Fig. 5A) . Further, at the peak of LCMV infection, we found higher parasite burden, a sign of reactivation of parasite proliferation (Fig. 5B ). The mechanism of relapse relied on Type I IFNs, since no footpad swelling or increase in parasite load was observed in ifnar-/-mice infected with either LgyLRV1 -or LgyLRV1+ (Fig. 5A-B ).
As seen with simultaneous infections, the subsequent delayed post-healing LCMV injection in LgyLRV1 -infected mice induced down-regulation of IFN-γR surface expression on macrophages in a Type I IFN-dependent manner (Fig. S7A ).
Interestingly, LgyLRV1+ infected WT mice developed only small lesions and parasite number compared to their LgyLRV1 -counterparts, thus reversing the phenotype observed in simple Lgy infection. Indeed, when LgyLRV1 -infected mice were injected with Type I IFNs during the first two days of infection, they developed less severe relapses when subsequently co-infected with LCMV ( Fig. 5C ). This result suggests that early Type I IFN production could significantly prevent the reactivation of the disease in mice previously infected with LgyLRV1+, thus explaining the difference between the LgyLRV1+ and LgyLRV1 -relapsing phenotype. Accordingly, the down-regulation of IFN-γR was not observed in LgyLRV1+ Significantly, exogenous viral co-infection with LCMV or TOSV worsened the outcome of murine leishmaniasis caused by LgyLRV1 -, reproducing the phenotype of LgyLRV1+ infected mice (Fig. 2) . It was recently reported that mice infected with LCMV present increased lesions when subsequently infected with L. major (46). This phenotype was due to an increased inflammatory response induced by memory T cells not accompanied by an increased parasite burden. Similar results were observed when mice were firstly infected with L. major and only two weeks later co-infected with LCMV (40). In this latter case, a transiently decreased anti-Leishmania immune response was observed one week following LCMV co-infection. In our experiments, mice were infected at the same time with parasites and LCMV, leading not only to increased footpad lesions, but also to higher parasite burden, compared to infection with parasites alone. This suggests that there was a decrease of macrophage anti-parasitic activity, consistent with the lower IFN-γR expression on macrophages, this observation, however, did not exclude other possible systemic effects of LCMV. Interestingly, LCMV co-infection was able to promote the metastatic phenotype in LgyLRV1 -infected IFN-γ-deficient mice (Fig. 4) . Further, we showed that disease exacerbation of LRV1 and LCMV co-infection depended completely on Type I IFNs ( Fig.   2A-B) .
These findings may explain why the tight correlation between disease severity and metastasis with LgyLRV1+ in animal models (5) may be more variable in humans (13, 17, 47, 48). Potentially, co-infection with viruses or other pathogens inducing a sufficient amount of Type I IFNs could increase the severity of Lgy infection, contributing to the development of more severe disease manifestations. Certainly, many viral diseases are found in Leishmania endemic regions which could contribute to increased disease severity (49). A number of arboviruses are transmitted by the sand fly vectors also transmitting Leishmania, including the Massilia and TOSV Phleboviruses (50, 51). Co-infection was reported in dogs, while seropositivity to TOSV was associated with L. infantum in humans (52, 53), however, the clinical relevance of the co-infection is unknown. Since our results suggest that events early in infection were crucial to determine the fate of the disease (Fig 1C-D) , having the virus transmitted simultaneously with Leishmania (Viannia) could magnify the impact of coinfection. However, intraperitoneal LCMV infections which induce a systemic Type I IFN response strongly exacerbated disease, suggesting that co-infections do not require the same entry site.
Finally, we showed that LCMV infection following the resolution of the primary lesion induced relapses of leishmaniasis, overriding the memory immune response of the host. Surprisingly, relapses were more severe in LgyLRV1 -infected mice compared to LgyLRV1+.
This result correlated with a Type I IFN dependent down-regulation of IFN-γR observed in
LgyLRV1 -infected mice compared to LgyLRV1+, confirming the role of IFN-γR in determining the outcome of the disease. Identification of the mechanism(s) underlying difference will require future investigation. In humans, relapses are observed following infection with different species of Leishmania and can have varying outcomes, ranging from a simple cutaneous lesion, to DCL or MCL in the case of Lgy or Lbr infection, or post-kala-azar dermal leishmaniasis, in the case of L. donovani infection (3, 54, 55). Here we suggest that viral co-infection and prior exposure to Type I IFNs could not only be a risk factor for relapses of leishmaniasis, but could be the trigger of parasite reactivation.
In total, our findings establish a major role for simultaneous or subsequent viral infection in determining the severity of Leishmania (Viannia) infection in animal models and that viral co-infections could contribute towards metastasis and relapse in human patients suffering from leishmaniasis.
Material and Methods
For additional information please refer to the SI text. 
Parasites and viruses
Matched LgyLRV1+ and LgyLRV1 -parasites expressing luciferase obtained following limited treatment with anti-LRV1 inhibitors were used in all studies (20). In vivo parasites were quantified by luciferase bioluminescence imaging as described previously (17).
LCMV and TOSV were provided by D. Zehn and M. G. Cusi, respectively.
Macrophages
Bone marrow derived macrophages were generated as described previously (18). 
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SI text
LgyLRV1+ infection induced Type I IFN expression in vivo
We previously demonstrated that macrophages produce IFN-β upon infection with LgyLRV1+ parasites in vitro (5) . To verify if similar production was occurring in vivo, C57BL/6 WT mice were inoculated with LgyLRV1+ or LgyLRV1-parasites in the hind footpad. At 6 or 12 hours post infection, mice were sacrificed, and the footpads and draining lymph nodes were recovered and used for RT-qPCR analysis. ifn-β transcription was upregulated at early time points post LgyLRV1+ infection in both footpads and draining lymph nodes (Fig. S8) . The increase of transcription was found to be only transient, as 48 hours post infection, Type I IFNs were not detectable neither in the lymph node, nor in the footpad.
Similar results were obtained for ifn-α (Fig. S8) . Further, in vivo macrophage depletion using clodronate-containing liposomes completely abrogated the induction of ifn-α and ifn-β, demonstrating that macrophages are responsible for Type I IFN production in LgyLRV1+ infection ( Fig. S8 and S9 ).
SI Material and methods
Mice
Four to 5 week old C57BL/6 mice were purchased from Harlan Laboratories 
Macrophage extraction and culture
In order to obtain bone marrow derived macrophages (BMDMs), bone marrow was extracted from tibias and femurs of C57BL/6 or ifnar-/-mice. Macrophages were cultured at 37°C and 5% CO 2 in 10ml of Dulbecco's modified eagle medium (DMEM, Gibco®)
supplemented with 10% of Fetal Calf Serum (FCS), 1% of P/S, 1% of HEPES (SigmaAldrich) and 50ng/ml of murine recombinant M-CSF (Immunotools). After 3 days, 5ml of fresh DMEM medium was added to the culture and 3 days later BMDMs were used for stimulation assays. 
IFN-γ receptor measurement
Parasite quantification
In vivo parasites were quantified at the peak of infection in mouse footpads by injecting 15mg/kg of luciferin (Invivo Imaging) intra-peritoneally and measuring the luminescence produced in the footpads with a Xenogen IVIS Lumina II. The following parameters were used: exposure 10 minutes, binning medium, F/stop 1.2. Alternatively, the Brucker Extreme II machine was used with the following parameters: exposure 5 minutes, binning 4, F/stop 1.2.
Macrophage depletion
To deplete macrophages from the draining lymph nodes, WT mice were injected subcutaneously into the ankle with 50µl of PBS-or Clodronate-containing liposomes (ClodronateLiposomes.org). Three weeks post-treatment, mice were infected with 3x10 
Statistical analysis
Data obtained from Xenogen and FACS were analyzed using either two-way ANOVA or Student's t-test. Data obtained from qRT-PCR and ELISA were analyzed using a Student's t-test. Data obtained from footpad swelling measurements were analyzed using a repeated measure ANOVA test. When the curves were non-parallel (i.e. the treatment-time interaction was statistically significant), statistical significance of difference between treatments at different time points was assessed using Bonferroni's multiple test correction.
Statistical significance was set at a p-value lower than 0.05. All data are represented with the mean ± the standard error of the mean (SEM). All analyses were performed using GraphPad Prism® software. Figure S1 . IFN-α injection increased the size of the lesions of LRV1-Lgy infected mice.
SI Figures
WT mice were infected in the hind footpads with 3 x 10 6 stationary phase Lgy promastigotes. WT mice were infected in the hind footpads with 3 x 10 6 Lgy stationary-phase promastigotes.
ifn-β and ifn-α transcript levels were quantified by RT-qPCR at 6 or 12 hours p.i. in footpads Results of one representative of 3 independent experiments were expressed as mean ± SEM (n=5) transcript increase relative to a naïve mouse and normalized to housekeeping gene l32.
Statistical significance was assessed by Student's t-test, *p<0.05, **p<0.01, ***p<0.001 . 
